HIV vaccine - PX Therapeutics
Alternative Names: EN41-FPA2 HIV; EN41-FPA2 HIV vaccine candidate - PX Therapeutics; EN41-UGR7C; EN41-UGR7C HIV vaccine candidate - PX Therapeutics; EuroNeut41 prophylactic HIV vaccine - PX Therapeutics; HIV vaccine - PX'TherapeuticsLatest Information Update: 24 Oct 2021
At a glance
- Originator PX Therapeutics
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in United Kingdom (IM, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in United Kingdom (Intranasal)
- 01 Feb 2014 PX Therapeutics completes a phase I trial of EN41-UGR7C for HIV infections (prevention; in volunteers) in United Kingdom (NCT01827397)